Whereas two of the previous studies included patients with moderate and severe AD (Kepe et al., 2006; Lanctôt et al., 2007), our results in very mild ‐ mild AD patients strengthen the evidence of decreased in vivo 5‐HT1A binding already in early AD (Truchot et al., 2007). This evidence concerns the gene HTR1A and Alzheimer disease.